Recent Finacing
Recent Raise
Bond Biosciences discovers and develops non‑absorbed oral therapeutics that locally bind excess ions in the gastrointestinal tract, including BBI‑001, a GI‑restricted iron chelator for hereditary hemochromatosis.
Focus Areas
Recent Investors
Funding rounds
Investor
See the team members at Bond Biosciences.
